CAR T Cell Therapy Market is Expected to be an Important Development in Cancer Treatment And Therapeutics Industry | Top Key Players Pfizer, Inc., Novartis International AG, Legend Biotech, Kite Pharma, Inc., Juno Therapeutics, Bluebird Bio, Inc.

CAR-T cell therapy is a novel immunotherapy that helps to treat various types of cancers. CAR-T cells are genetically engineered cell receptors that are attached to the T-cells of the cancer patients and infused through the blood stream that activates immune system to kill the cancer causing cells in the body. The T-cells injected into the patient’s body aids in reducing the risk of recurrence of tumor and thus, acts as a cure treatment for patients suffering with blood cancer. The CAR-T cell therapy is a solution to overcome the disease progression, identify the cancer causing cells, and kill them using body’s own immune system and defense mechanism.

For Better Understanding – You Can Request Sample Copy of Report Before Buying Here: https://www.coherentmarketinsights.com/insight/request-sample/102

Market Dynamics

CAR-T cell therapy is expected to be an important development in cancer treatment and therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading to high demand for its treatment. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases would be observed worldwide. Moreover, introduction of new therapies into the market is further expected to bolster growth of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. However, risks of side effects resulting in various neurological disorders is expected to hinder growth of the global CAR-T cell therapy market.

The global CAR-T Cell therapy market is estimated to be valued at US$ 295.1 million in 2018 and is expected to witness a CAGR of 32.5 % over the forecast period (2018 – 2028).

Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the global CAR-T cell therapy market. Rising number of adults and children developing cancer is expected to lead to high demand for an effective and reliable therapeutic treatment approach for improvement of quality of patient’s lives. The Cancer Research UK reported that over 14.1 million cancer cases occurred in 2012 across the world. Moreover, according to the Leukemia and Lymphoma Society of Canada, around 22,340 people in Canada were diagnosed with some form of blood cancer, of which 9,000 cases were lymphoma.

Moreover, development of new and effective therapy options to cure symptoms of the disease is also a vital factor contributing to growth of CAR-T cell therapy market. In 2017, the U.S. Food and Drug Administration approved two CAR-T cell therapies Kymriah and Yescarta for children and adult lymphoblastic leukemia and advanced lymphoma in adults, respectively. This is expected to aid in growth of the market over the forecast period.

Furthermore, increasing government initiatives for improving health care infrastructure and promoting research for cell therapy in cancer is fueling growth of the market. For instance, in December 2016, the National Cancer Advisory Board authorized US$ 1.8 Bn in funding for Cancer Moonshot, which is an initiative taken up to accelerate research with an aim to make more therapies available to patients with cancer.

Market players are engaged in developing and launching innovative products and adopt merger and acquisition strategies to retain position in the global CAR-T cell therapy market

Key players in the market are engaged in extensive research and development to launch new targeted cell therapies in the market. For instance, the University of Texas MD Anderson Cancer Center, Houston is conducting phase 1 clinical trial studies of central memory–derived CD19 CAR T–cell therapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma. Moreover, key players are focusing on strategic merger and acquisition to enhance their share in the global CAR-T cell therapy market. For instance, in April 2018, Pfizer, Inc. signed a deal with Allogene, to develop an investigational CAR-T cell therapy for treating cancer.

Key players operating in the global CAR-T cell therapy market include Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen Therapeutics, Ltd., and others.

Do Inquire More or Share Your Questions Before Buying CAR T Cell Therapy Market Report: https://www.coherentmarketinsights.com/insight/talk-to-analyst/102

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.